BMA, short for BMA Biomedicals, is a small biotech company located in the Basel area in northern Switzerland.
Founded in 1989 by a group of immunologists, biochemists and biologists, its main area of activity is in the development, production and marketing of antibodies. In 2005, BMA was acquired by Chemoforma Inc., a long-time business partner active in the production of immune-supportive feed additives. In 2013, Chemoforma Inc. acquired Peninsula Laboratories International, Inc., a California-based company specialized in anti-peptide antibodies and radioimmunoassays.
BMA's main expertise lies in the application of antibodies in immunohistochemistry and enzyme immunoassays (ELISAs). Production has fully been adapted to culture media without fetal calf serum. This is not only an important contribution to sustainability and animal welfare, but the products contain no contaminating bovine antibodies. They are generally offered for in vitro research use only, but the licensing of appropriate products to companies in the diagnostics field is supported.